Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.42 |
| ▸ | ABL1 | P00519 | 2/20 | 0.42 |
| ▸ | USP7 | Q93009 | 5/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | CD44 | P16070 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | FLT1 | P17948 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.33 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24286636 | 0.87 | LRRK2 (0.55) | LRRK2ABL1USP7TGFBR1CDK2 | |
| SCHEMBL29537041 | 0.74 | LRRK2 (0.53) | LRRK2ABL1CDK2 | |
| SCHEMBL24285994 | 0.74 | LRRK2 (0.53) | LRRK2ABL1CDK2 | |
| SCHEMBL24286669 | 0.72 | LRRK2 (0.43) | LRRK2ABL1USP7TGFBR1SRC | |
| SCHEMBL24286579 | 0.70 | ABL1 (0.47) | LRRK2ABL1USP7TGFBR1SRC | |
| SCHEMBL9924061 | 0.69 | PIK3CD (0.49) | USP7CDK2SMN1; SMN2 | |
| SCHEMBL22363049 | 0.69 | USP7 (0.40) | LRRK2ABL1USP7CDK2APP | |
| SCHEMBL25011940 | 0.69 | CD44 (0.54) | CD44DPP4SRCHPGDSMN1; SMN2 | |
| SCHEMBL24285885 | 0.69 | LRRK2 (0.41) | LRRK2ABL1USP7TGFBR1CDK2 | |
| SCHEMBL24286655 | 0.69 | MAPT (0.47) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220087985-A1 | 2-AMINO-3-CARBONYL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE COMPOUNDS | 1ST Biotherapeutics, Inc. (KR) | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220087985-A1 | 2-AMINO-3-CARBONYL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE COMPOUNDS | NLRP3, NLRP1, KCNJ2 | LRRK2 538/4885ABL1 966/4885USP7 4519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.